Algernon Pharmaceuticals Inc (CSE:AGN) (OTCB:BTHCF) announced Friday that Dr Mark Swaim, a former practicing physician and researcher, has joined the Algernon Medical and Scientific Advisory Board.
Dr Swaim graduated from Duke University where he was a National Institutes of Health-sponsored Medical Scientist Training Program scholar and was elected to the Alpha Omega Alpha Honor Medical Society and served as its president, according to a statement.
He completed post-graduate training in internal medicine, gastroenterology, and hepatology at Duke University Medical Center and post-doctoral research at National Taiwan University in Taipei. Dr Swaim served on the faculties of Duke University Medical Center, University of Texas MD Anderson Cancer Center, and the McGovern Medical School of the University of Texas in Houston.
In other company news, Algernon said that due to a lack of sufficiently ill patients, which is a direct result of a highly successful government initiated pandemic mitigation strategy, the company has decided to close the investigator-led South Korea trial of Ifenprodil (NP-120) to treat COVID-19.
Instead, the company will remain focused on its Phase 2b/3 multinational Ifenprodil COVID study, which currently has enrolled more than 75% of its target enrollment.
Algernon has projected that the Phase 2b/3 study will be completed in November 2020, with a planned data readout before the end of the fourth quarter of 2020.
“I am very pleased that Dr Swaim has accepted our invitation to join our Advisory Board and we look forward to working closely with him,” said Algernon CEO Christopher Moreau. “We also look forward to reaching 100% of our enrollment target of our multinational Ifenprodil Phase 2b/3 study for COVID shortly.”
Prevent cytokine storm?
Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.
The company believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients.
Algernon, based in Vancouver, is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the US or Europe to avoid off-label prescription writing.
Contact the author: firstname.lastname@example.org
Follow him on Twitter @PatrickMGraham